logo
Plus   Neg
Share
Email

ISoftStone Holdings Q1 Profit Decreases - Quick Facts

iSoftStone Holdings Ltd. (ISS) posted first-quarter net income of $3.3 million versus $5.2 million last year. Earnings per American Depositary Share, or ADS, were $0.06 compared to $0.09 a year ago.

Non-GAAP net income rose 19% to $7.3 million from $6.2 million in the first quarter of 2011. Non-GAAP earnings per ADS grew to $0.12 from $0.10 in the previous year.

Net revenues surged 51.7% to $86.3 million from $56.9 million in the prior year.

Analysts polled by Thomson Reuters expected the company to earn $0.13 per share on revenues of $79.52 million for the quarter. Analysts' estimates typically exclude special items.

For the second quarter of 2012, iSoftStone expects net income to be at least $4.3 million. Non-GAAP net income for the quarter is expected to be at least $8.2 million and non-GAAP earnings per ADS to be at least $0.14. Net revenues for the second quarter are anticipated to be at least $90 million. Analysts expect the company to earn $0.18 per share on revenues of $89.35 million for the quarter.

For 2012, the company expects net income to be at least $31 million. On a non-GAAP basis, net income is expected to be at least $45 million and earnings per ADS is expected to be at least $0.73. Net revenues in 2012 are expected to be at least $382 million. Analysts expect the company to earn $0.74 per share on revenues of $375.11 million for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT